The p53 gene and its role in human brain tumors

Glia

Volumn 15, Issue 3, 1995, Pages 308-327

  Bögler, Oliver ^a   Su Huang, H J ^a   Kleihues, Paul ^b   Cavenee, Webster K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Growth regulation; Oncogene; Tumor suppressor gene

Indexed keywords

PROTEIN P53;

AMINO ACID SEQUENCE; BRAIN TUMOR; CELL DEATH; CELL DIVISION; DNA DAMAGE; GENETIC TRANSCRIPTION; GENETICS; GLIOMA; HUMAN; MOLECULAR GENETICS; MUTATION; PATHOLOGY; PHYSIOLOGY; REVIEW; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; BRAIN NEOPLASMS; CELL DEATH; CELL DIVISION; DNA DAMAGE; GENES, P53; GERM-LINE MUTATION; GLIOMA; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029397307     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.440150311     Document Type: Article

References (214)

1. The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif
2. Heterogeneity of subcellular localization of p53 protein in human glioblastomas
3. p53 protein accumulation and gene mutations in human glioma cell lines
4. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas
5. Suppression of human colorectal carcinoma cell growth by wild‐type p53
6. Regulation of mdm2 expression by p53: Alternative promoters produce transcripts with nonidentical translation potential
7. Wild‐type but not mutant p53 immunopurified proteins bind to sequences adjacant to the SV40 origin of replication
8. Site‐specific binding of a wild‐type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53
9. A proteolytic fragment from the central region of the p53 has marked sequence‐specific DNA‐binding activity when generated from wild‐type but not from oncogenic mutant p53 protein
10. Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroeukemic cell lines induced by Friend leukemia virus
11. Evidence for a 17‐p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors
12. Gene amplification in malignant human gliomas: Clinical and histopathological aspects
13. Spontaneous abnormalities in normal fibroblasts from patients with Li‐Fraumeni cancer syndrome: Aneuploidy and immortalization
14. Human p53 is phosphorylated by p60‐cdc2 and cyclin B‐cdc2
15. Escape from senescence in human diploid fibroblasts induced directly by mutant p53
16. Loss of wild‐type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation
17. The tumor suppressor p53 and oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein
18. Growth suppression of human breast cancer cells by the introduction of a wild‐type p53 gene
19. Accumulation of genetic defects during astrocytoma progression
20. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway
21. Mapping of the p53 and mdm‐2 interaction domains
22. Modulation of activity of the promotor of the human MDR1 gene by ras and p53
23. Crystal structure of a p53 tumor suppressor‐DNA complex: Understanding tumorigenic mutations
24. Multistage Friend erythroleukemia: Independent origin of tumor clones with normal or rearranged p53 cellular oncogenes
25. TP53 gene mutations and 17p deletions in human astrocytomas
26. Thymocyte apoptosis induced by p53 dependent and independent pathways
27. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma
28. High‐resolution structure of the oligomerization domain of p53 by Multidimensional NMR
29. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin
30. TP53 tumor suppressor gene: A model for investigating human mutagenesis
31. Timing of p53 mutations during astrocytoma tumorigenesis
32. Detection of a transformation‐related antigen in chemically induced sarcomas and other transformed cells of the mouse
33. p53 functions as a cell cycle control protein in osteosarcomas
34. Gain of function mutations in p53
35. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
36. p53‐dependent inhibition of cyclin‐dependent kinase activities in human fibroblasts during radiation‐induced G1 arrest
37. Inhibition of DNA replication factor RPA by p53
38. Genes for epidermal growth factor receptor, transforming growth factor a, and epidermal growth factor and their expression in human gliomas in vivo
39. Loss of distinct regions on the short arm of chromosome 17 associated with tumorigenesis of human astrocytomas
40. Definition of a consensus binding site for p53
41. WAF1, a potential mediator of p53 tumor suppression
42. WAF1/CIP1 is induced in p53‐mediated G1 arrest and apoptosis
43. Participation of p53 cellular tumor antigen in transformation of normal embryonic cells
44. Wild‐type p53 can inhibit oncogene‐mediated focus formation
45. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line
46. Wild‐type p53 activates transcription in vitro
47. A genetic model for colorectal tumorigenesis
48. Presence of a potent transcription activating sequence in the p53 protein
49. The mdm‐2 oncogene can overcome wild‐type p53 suppression of transformed cell growth
50. Activating mutations for transformation by p53 produce a gene product that forms an hsc70‐p53 complex with an altered half‐life
51. The p53 proto‐oncogene can act as a suppressor of transformation
52. The role of angiogenesis in tumor growth
53. Angiogenesis in cancer, vascular, rheumatoid and other disease
54. Isolation and characterization of DNA sequences that are specifically bound by wild‐type p53 protein
55. p53 mutations in human malignant gliomas: Comparison of loss of heterozygosity with mutation frequency
56. A functional screen for germ line p53 mutations based on transcriptional activation
57. The p53 protein is an unusually shaped tetramer that binds directly to DNA Proc
58. p53: A glimpse at the puppet behind the shadow play
59. A retroviral wild‐type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis
60. p53 mutations and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression
61. A transcriptionally active DNA‐binding site for human p53 protein complexes
62. Protein synthesis required to anchor a mutant p53 protein which is temperature‐sensitive for nuclear transport
63. Induction of growth arrest by a temperature‐sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein
64. Wild‐type p53 can down‐modulate the activity of various promoters, Proc
65. A structural role for metal ions in the “wild‐type” conformation of the tumor suppressor protein p53
66. Redox modulation of p53 conformation and sequence‐specific DNA binding in vitro
67. Physical and functional interaction between wild‐type p53 and mdm2 proteins
68. Stabilization of the p53 transformation‐related protein in mouse fibrosarcoma cell lines: Effects of protein sequence and intracellular environment
69. Different tumor‐derived p53 mutants exhibit distinct biological activities
70. The p2l Cdk‐interacting protein Cip1 is a potent inhibitor of G1 cyclin‐dependent kinases
71. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells
72. Cell cycle control and cancer
73. Spontaneous and carcinogen‐induced tumorigenesis in p53‐deficient mice
74. In vitro growth characteristics of embryo fibroblasts isolated from p53‐deficient mice
75. Timing and role of p53 gene mutation in the recurrence of glioma
76. Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53‐plus‐ras‐transformed cell lines, Mol
77. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells; A comparison of the “hot spot” mutant phenotypes
78. p53 mutations in human cancers
79. Database of p53 gene somatic mutations in human tumors and cell lines
80. p53 gene mutations in brain tumors in Taiwan
81. Regulation of the specific DNA binding function of p53
82. Wild‐type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles
83. Localization of gene for human p53 tumor antigen to band 17pl3
84. Cellular immortalization by a cDNA clone encoding the transformation associated phosphoprotein p53
85. Expression of wild‐type p53 is not compatible with continued growth of p53‐negative tumor cells
86. Participation of p53 protein in the cellular response to DNA damage
87. , A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia‐telangiectasia
88. Identification of p53 as a sequencespecific DNA‐binding protein
89. Oncogenic forms of p53 inhibit p53‐regulated gene expression
90. Turcot's syndrome of glioma and polyposis occurs in the absence of germ line mutations of exons 5 to 9 of the p53 Gene
91. Analysis of p53 gene mutation‐sin low‐ and high‐grade astrocytomas by polymerase chain reaction‐ assisted single‐strand conformation polymorphism and immunocytochemistry
92. TP53 alterations and clinical outcome in low grade astrocytomas
93. Wild‐type p53 is a cell cycle checkpoint determinant following irradiation
94. Germline p53 gene mutations in subsets of glioma patients‐ J
95. p53, guardian of the genome
96. T antigen is bound to a host protein in SV40‐transformed cells
97. Pathways leading to glioblastoma multiforme; A molecular analysis of genetic alterations in 65 astrocytic tumors
98. High incidence of lung, bone, and lymphoid tumors in transgenic mice overxpressing mutant alleles of the p53 oncogene
99. p53 mutations increase resistance to ionizing radiation
100. Molecular characterisation of areas with low grade tumor or satellitosis in human malignant astrocytomas
101. Human cells contain a DNA‐activated protein kinase that phosphorylates simian virus 40 T antigen, mouse p53, and the human Ku autoantigea, Mol
102. Neoplasms of the central nervous system
103. Complementation by wild‐type p53 of interleukin‐6 effects on Ml cells: Induction of cell cycle exit and cooperativity with c‐myc suppression
104. Differential effects by the p21 CDK inhibitor on PC NA‐dependent DNA replication and repair
105. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin
106. Growth arrest induced by wild‐type p53 protein blocks cells prior to or near the restriction point in late G1 phase
107. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40‐transformed cells and uninfected embryonal cells
108. Altered cell cycle arrest and gene amplification potential accompany loss of wild‐type p53
109. Comparative study of p53 gene and protein alterations in human astrocytic tumors
110. Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens
111. p53 is required for radiation‐induced apoptosis in mouse thymocytes
112. p53‐dependent apoptosis modulates the cytotoxicity of anticancer agents
113. p53 status and the efficacy of cancer therapy in vivo
114. Familial brain tumour syndrome associated with a p53 germ‐line deletion of codon 236
115. Specific repression of TATA‐mediated but not initator‐mediated transcrption by wild‐type p53
116. The Li‐Fraumeni syndrome
117. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
118. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells
119. Tumor suppressor genes
120. Cellular localization and cell cycle regulation by a temperature‐sensitive p53 protein
121. Detection of p53 gene mutations in human brain tumors by single‐strand conformation polymorphism analysis of polymerase chain reaction products
122. Rearrangement of the p53 gene in human osteogenic sarcomas
123. The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase IT
124. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild‐type p53, Proc
125. Growth suppression induced by wild‐type p53 proteins is accompanied by selective down‐regulation of proliferating‐cell nuclear antigen expression
126. Identification of a germ‐line mutation in the p53 gene in a patient with an intracranial ependymoma
127. Conditional inhibition of transformation and of cell proliferation by a temperature‐sensitive mutant of p53
128. Induction of WAF1/CIP1 by a p53‐independent pathway
129. Phosphorylation of the p53 tumor‐suppressor protein at the three N‐terminal sites by a novel casein kinase I‐like enzyme
130. Cotranslation of activated mutant p53 with wild type drives the wild‐type p53 protein into the mutant conformation
131. Tumor suppressor p53 is a direct transcriptional activator of the human box gene
132. The mdm‐2 oncogene product forms a complex with the p53 protein and inhibits p53‐mediated transactivation
133. Biochemical properties of the growth suppressor/oncoprotein p53
134. p53 and mdm2 are expressed independently during cellular proliferation
135. Mechanisms of p53 loss in human sarcoma
136. A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme
137. Retinoblastoma
138. Mutations in the p63 gene occur in diverse human tumour types
139. The clonal evolution of tumor cell populations
140. p53 mutations in nonastrocytic human brain tumors
141. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system, Mol
142. Genetic alterations associated with the evolution and progression of astrocytic brain tumors
143. Amplification of a gene encoding a p53‐associated protein in human sarcomas
144. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
145. Identification and characterization of multiple mdm‐2 proteins and mdm‐2‐p53 protein complexes
146. A potential transcriptional activation element in the p53 protein
147. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation
148. The DNA‐binding domain of p53 contains the four conserved regions and the major mutation hot spots
149. The mdm‐2 gene is induced in response to UV light in a p53‐dependent manner, Proc
150. Joining the complex: Cyclin‐dependent kinase inhibitory proteins and the cell cycle
151. The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53?
152. Solid tumors of childhood
153. Expression of p53 in human leukemia and lymphoma
154. Alterations of the TP53 gene in human gliomas
155. Transcriptional activation by wild‐type but not transforming mutants of the p53 anti‐oncogene
156. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations
157. Immortalization of rat embryo fibroblasts by the cellular p53 oncogene
158. Accumulation of wild type p53 protein in human astrocytomas
159. Cell cycle analysis of p53‐induced cell death in murine erythroleukemia cells
160. p53 induction is associated with neuronal damage in the central nervous system
161. Mechanisms of DNA excision repair
162. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product, Proc
163. Analysis of p53 gene mutations in human gliomas by polymerase chain reaction‐based single‐strand conformation polymorphism and DNA sequencing
164. Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas
165. Infrequent p53 gene mutations in medulloblastoma
166. Wild‐type p53 binds to the TATA‐binding protein and represses transcription, Proc
167. Nuclear localization is essential for the activity of p53 protein
168. Induction of apoptosis by wild‐type p53 in a human colon tumor‐derived cell line
169. Negative regulation of Rb expression by the p53 gene product, Proc
170. Clonal expansion of p53 mutant cells is associated with brain tumour progression
171. Loss of a p53‐associated G1 checkpoint does not decrease cell survival following DNA damage
172. Transforming activity of mutant human p53 Alleles
173. Interaction of the p53‐regulated protein Gadd45 with proliferating cell nuclear antigen
174. Structural aspects of the p53 protein in relation to gene evolution
175. Germ‐line transmission of a mutated p53 gene in a cancerprone family with Li‐Fraumeni syndrome
176. Detection of both mutant and wild‐type p53 protein in normal skin fibroblasts and demonstration of a shared second hit' on p53 in diverse tumors from a cancer‐prone family with Li‐Fraumeni syndrome
177. Dominant negative effect of a germ‐line mutant p53: A step fostering tumorigenesis
178. Several mutant p53 proteins detected in cancer‐prone families with Li‐Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild‐type p53
179. Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library
180. Characterization of mutant p53‐hsp72/73 protein‐protein complexes by transient expression in monkey COS cells
181. p53 interacts with p34cdc2 in mammalian cells: Implications for cell cycle control and oncogenesis
182. Inhibition of viral and cellular promoters by human wild‐type p53
183. p53‐dependent apoptosis suppresses tumor growth and progression in vivo
184. Altered structure and expression of the p53 gene in human neuroepithelial tumors
185. p53 mutations and microsatellite analysis of loss of heterozygosity in malignant gliomas
186. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60
187. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells
188. Human wild‐type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells
189. p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer
190. Functional domains of wild‐type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression
191. Analysis of the p53 gene and its expression in human glioblastoma cells
192. Release of an inhibitor of angiogenesis upon induction of wild‐type p53 expression in glioblastoma cells
193. Single‐cell monitoring of growth arrest and morphological changes induced by transfer of wild type p53 alleles into glioblastoma cells
194. p63 mutation, expression, and DNA ploidy in evolving gliomas: Evidence for two pathways of progression
195. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma
196. Deletions on the long arm of chromosome 17 in pilocytic astrocytoma
197. The p21 inhibitor of cyclin‐dependent kinases controls DNA replication by interaction with PCNA
198. Phosphorylation sites in the aminoterminal region of mouse p53
199. The MCK enhancer contains a p53 responsive element
200. Frequency of p53 tumor suppressor gene mutations in human primary brain tumors
201. The p53‐mdm‐2 autoregulatory feedback loop
202. p21 is a universal inhibitor of cyclin kinases
203. Astrocytes derived from p53‐deficient mice provide a multi‐step in vitro model for development of malignant gliomas
204. Wild‐type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 Alleles
205. Wild‐type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin‐6
206. p53‐mediated cell death: Relationship to cell cycle control
207. Wild‐type p53 mediates positive regulation of gene expression through a specific DNA sequence element
208. Correlation between the conformational phenotype of p53 and its subcellular location
209. The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth
210. p53 gene mutations in pontine gliomas of juvenile onset
211. Inactive p53 mutants may enhance the transcriptional activity of wild‐type p53